Cox-2 Inhibition Enhances the Activity of Sunitinib in Human Renal Cell Carcinoma Xenografts

DSpace/Manakin Repository

Cox-2 Inhibition Enhances the Activity of Sunitinib in Human Renal Cell Carcinoma Xenografts

Citable link to this page

 

 
Title: Cox-2 Inhibition Enhances the Activity of Sunitinib in Human Renal Cell Carcinoma Xenografts
Author: Wang, Xiaoen; Zhang, L; O'Neill, A; Bahamon, B; Alsop, David C.; Mier, James W.; Goldberg, S. Nahum; Signoretti, Sabina; Atkins, M B; Wood, C G; Bhatt, Rupal Satish

Note: Order does not necessarily reflect citation order of authors.

Citation: Wang, Xiaoen, L. Zhang, A. O'Neill, B. Bahamon, David C. Alsop, James W. Mier, S. Nahum Goldberg, et al. 2013. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. British Journal of Cancer 108(2): 319-326.
Full Text & Related Files:
Abstract: Background: Sunitinib (Su), a tyrosine kinase inhibitor of VEGFR, is effective at producing tumour response in clear cell renal cell carcinoma (cRCC), but resistance to therapy is inevitable. As COX-2 is a known mediator of tumour growth, we explored the potential benefit of COX-2 inhibition in combination with VEGFR inhibition in attempts at delaying tumour progression on Su. Methods: COX-2 expression was compared with areas of hypoxia in tumours that progressed on Su vs untreated tumours. Mice bearing human cRCC xenografts were treated with Su and the COX-2 inhibitor, celecoxib, and the effects on tumour growth were assessed. Sequential vs concurrent regimens were compared. Results: COX-2 expression was increased in cRCC xenografts in areas of tumour hypoxia. The combination of Su and celecoxib achieved longer times to tumour progression compared to treatment with either agent alone or to untreated control animals in four models. This effect was seen with concurrent but not with sequential therapy. Conclusion: COX-2 inhibition can extend the effectiveness of VEGFR inhibition. This effect is dependent on the timing of therapy. Clinical trials combining Su and COX-2 inhibitors should be considered as a means delaying time to progression on sunitinib in patients with metastatic cRCC.
Published Version: doi:10.1038/bjc.2012.591
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566808/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10708072
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters